198 related articles for article (PubMed ID: 25909786)
1. [Venlafaxine in the treatment of moderate and severe depressions: the ways to increase treatment efficacy].
Ivanets NN; Kinkulkina MA; Tikhonova YG; Iziumina TA
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):30-34. PubMed ID: 25909786
[TBL] [Abstract][Full Text] [Related]
2. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
3. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
Bauer M; Tharmanathan P; Volz HP; Moeller HJ; Freemantle N
Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors.
Sáiz-Ruiz J; Ibáñez A; Díaz-Marsá M; Arias F; Padín J; Martín-Carrasco M; Montes JM; Ferrando L; Carrasco JL; Martín-Ballesteros E; Jordá L; Chamorro L
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1129-34. PubMed ID: 12452535
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
[TBL] [Abstract][Full Text] [Related]
7. [Velaxin (venlafaxine) in the treatment of anxious depression].
Il'ina NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):24-8. PubMed ID: 18427537
[TBL] [Abstract][Full Text] [Related]
8. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.
Shea ML; Garfield LD; Teitelbaum S; Civitelli R; Mulsant BH; Reynolds CF; Dixon D; Doré P; Lenze EJ
Osteoporos Int; 2013 May; 24(5):1741-9. PubMed ID: 23358607
[TBL] [Abstract][Full Text] [Related]
9. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.
Einarson TR; Arikian SR; Casciano J; Doyle JJ
Clin Ther; 1999 Feb; 21(2):296-308. PubMed ID: 10211533
[TBL] [Abstract][Full Text] [Related]
10. [Pharma-Clinics. The drug of the month. Venlafaxine (Efexor)].
Ansseau M
Rev Med Liege; 1998 Feb; 53(2):106-8. PubMed ID: 9564231
[TBL] [Abstract][Full Text] [Related]
11. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
12. [Effects of venlafaxine extended release formulation on the clinical management of patients].
Carrasco JL; Díaz-Marsá M; López-Ibor JJ
Actas Esp Psiquiatr; 2005; 33(3):147-53. PubMed ID: 15918081
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study.
Dias RS; Kerr-Corrêa F; Moreno RA; Trinca LA; Pontes A; Halbe HW; Gianfaldoni A; Dalben IS
Menopause; 2006; 13(2):202-11. PubMed ID: 16645534
[TBL] [Abstract][Full Text] [Related]
14. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies.
Thase ME; Shelton RC; Khan A
J Clin Psychopharmacol; 2006 Jun; 26(3):250-8. PubMed ID: 16702889
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
Kaplan EM
Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
[TBL] [Abstract][Full Text] [Related]
16. Experience of the use of velaxin (venlafaxine) in anxious depression.
Il'ina NA
Neurosci Behav Physiol; 2009 Mar; 39(3):305-9. PubMed ID: 19234798
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
Schatzberg A; Roose S
Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.
Charlier C; Pinto E; Ansseau M; Plomteux G
J Psychopharmacol; 2002 Dec; 16(4):369-72. PubMed ID: 12503838
[TBL] [Abstract][Full Text] [Related]
19. Differential physiological effects of a low dose and high doses of venlafaxine in major depression.
Debonnel G; Saint-André E; Hébert C; de Montigny C; Lavoie N; Blier P
Int J Neuropsychopharmacol; 2007 Feb; 10(1):51-61. PubMed ID: 16690006
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
Costa e Silva J
J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
